Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have
metastatic breast cancer. Imatinib mesylate may stop the growth of cancer by blocking the
enzymes necessary for tumor cell growth